NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Sumanta Pal
Beckman Research Institute of City of Hope - Kaliforniya / United States
Others
AD Scientific Index ID: 4613629
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Sumanta Pal's MOST POPULAR ARTICLES
1-)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialP Sharma, M Retz, A Siefker-Radtke, A Baron, A Necchi, J Bedke, ...The lancet oncology 18 (3), 312-322, 201714152017
2-)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinomaDF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...Nature medicine 24 (6), 749-757, 201810452018
3-)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trialTK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ...The lancet oncology 17 (7), 917-927, 201610422016
4-)
Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncologyTW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ...Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 20205382020
5-)
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database ConsortiumDYC Heng, JC Wells, BI Rini, B Beuselinck, JL Lee, JJ Knox, ...European urology 66 (4), 704-710, 20145092014
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept